Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis

Disorders in complement regulation are a major cause of atypical haemolytic–uraemic syndrome (aHUS). Eculizumab, a monoclonal antibody targeting complement C5 and blocking the terminal complement cascade, should theoretically be useful in this disease, particularly when associated with specific comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jon Jin, Waller, Simon C., Reid, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Clinical Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400463/
https://www.ncbi.nlm.nih.gov/pubmed/26069744
http://dx.doi.org/10.1093/ndtplus/sfr174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400463/
https://www.ncbi.nlm.nih.gov/pubmed/26069744
http://dx.doi.org/10.1093/ndtplus/sfr174

Ejemplares similares